36 -12 (62) 2023 — Davronova H.Z. — INFLUENCE OF SEVERITY OF TYPE II DIABETES MELLITUS ON THE DEVELOPMENT OF COGNITIVE DYSFUNCTIONS

INFLUENCE OF SEVERITY OF TYPE II DIABETES MELLITUS ON THE DEVELOPMENT OF COGNITIVE DYSFUNCTIONS

Davronova H.Z.  Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Diabetes mellitus (DM) type 2 is one of the significant independent risk factors for the development of cognitive impairment (CI) and dementia. The presence of possible CIs or their development in a patient with diabetes must be taken into account when selecting complex therapy. Treatment of each patient with diabetes should be individual, taking into account clinical characteristics, possible complications and the presence of comorbid vascular diseases. When choosing medications that improve cognitive function, in addition to the direct effect, one should take into account their other positive effects, as well as their tolerability and the possibility of safe combination as part of complex therapy.

Key words: Diabetes mellitus, cognitive impairment, dementia

First page

196

Last page

202

For citation: Davronova H.Z. – INFLUENCE OF SEVERITY OF TYPE II DIABETES MELLITUS ON THE DEVELOPMENT OF COGNITIVE DYSFUNCTIONS //New Day in Medicine 2023 12(62): 196-202 https://newdaymedicine.com/index.php/2023/12/14/l-590/

LIST OF REFERENCES:

1. Abbatecola A.M., Rizzo M.R., Barbieri M. et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics // Neurology, 2006;67:235-240.
2. Alafuzoff I., Aho L., Helisalmi S. et al. β-Amyloid deposition in brains of subjects with diabetes // Neuropathol. Appl. Neurobiol., 2009;35:60-68.
3. Arvanitakis Z. et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons // Neurology, 2006;67:1960-1965.
4. Beeri M. et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology // Neurology, 2008;71;750-757.
5. Biessels G.J., Staekenborg S., Brunner E., et al. Risk of dementia in diabetes mellitus: a systematic review // Lancet Neurol., 2006;5:64-74.
6. Craft S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia // Arch. Neurol., 2009;66:300-305.
7. DCCT/EDIC Study Recearch Group. Long-Term effect of diabetes and its treatment on cognitive function // New Engl. J. Med., 2007;356:1842-1852.
8. Irie F., Fitzpatrick A.L., Lopez O.L. Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE-4 // Arch. Neurol., 2008;65:89-93.
9. Kalaria R.N. Diabetes, microvascular pathology and Alzheimer disease // Nature Rev. Neurology, 2009;5:305-306.
10. Рахматова Д.И., Пулатов С.С. (2016). Особенности течения инволюционной эпилепсии. // Биология и интегративная медицина, 2016;1:70-82.
11. Ismatilloyevna R.D. (2022). The effectiveness of neuroprotective therapy in ischemic stroke. // European journal of modern medicine and practice, 2022;2(1):17-21.
12. Рахматова Д.И. (2019). Нетрадиционные методы терапии невропатии лицевого нерва на разных этапах развития заболевания. //Проблемы биологии и медицины, 2019;2(107):180-183.
13. Рахматова Д.И. (2022). Новые Возможности Оценки Лечения У Больных С Невропатией Лицевого Нерва Коморбидных С Сахарным Диабетом. Amaliy va tibbiyot fanlari ilmiy jurnali, 2022;1(7):38-43.
14. Рахматова Д.И. (2021). Значение нейровизуализационного метода ислледования в диагностике осложнённых форм невропатии лицевого нерва. // Журнал неврологии и нейрохирургических исследований, 2021;2(3).
15. Саломова Н. К. (2021). Особенности течения и клинико-патогенетическая характеристика первичных и повторных инсультов. // Central Asian Journal of Medical and Natural Science, 2021;249-253.
16. Саломова Н.Қ. (2023). Қайта ишемик инсультларнинг клиник потогенитик хусусиятларини аниқлаш. // Innovations in Technology and Science Education, 2023;2(8):1255-1264.
17. Salomova N.K. (2022). Risk factors for recurrent stroke. Polish journal of science N, 2022;52:33-35.
18. Qahharovna, S. N. (2023). Thromboocclusive Lesions of the Bronchocephalic Arteries: Treatment Options and Phytotherapy Options. American journal of science and learning for development, 2023;2(2):41-46.
19. Salomova Nilufar Kakhorovna Features of neurorehabilitation itself depending on the pathogenetic course of repeated strokes, localization of the stroke focus and the structure of neurological deficit // European Journal of Research Development and Sustainability (EJRDS 2022;11:8-12.)
20. Salomova N. K. (2022). Risk factors for recurrent stroke. Polish journal of science N, 2022;52:33-35.